脑血管病的多组学研究

doi:10.3969/j.issn.1673-5765.2025.06.001

摘要/Abstract

摘要： 目前，脑血管病在机制解析、专病队列建设和新药研发等方面仍面临挑战，而多组学的发展为理解其复杂的病理生理调控机制、优化疾病分型和诊断、提升预后预测能力，以及推进新药研发进程等提供了驱动力。同时，我国已建立万人级的中国脑血管病多组学多模态数据库STROMICS，并将进一步构建更加完善的脑血管病多组学专病队列，通过孟德尔随机化等跨学科方法推进多组学研究，为深入了解脑血管病的发生发展调控机制和推进新药研发提供研究方法。

关键词: 脑血管病; 卒中; 多组学

Abstract: Currently, cerebrovascular disease still faces challenges in elucidating mechanisms, constructing specialized cohorts, and developing new drugs. The advancement of multi-omics has provided a driving force for understanding the complex pathophysiological regulatory mechanisms, optimizing disease classification and diagnosis, enhancing prognosis prediction capabilities, and advancing the new drug development process. China has established the STROMICS database, a multi-omics and multimodal database of cerebrovascular disease at the ten-thousand-person level. China will further develop a more comprehensive multi-omics cohort for cerebrovascular disease and advance multi-omics research through interdisciplinary approaches such as Mendelian randomization. This will provide methods to deepen the understanding of the regulatory mechanisms underlying cerebrovascular disease and to facilitate new drug development.

Key words: Cerebrovascular disease; Stroke; Multi-omics

中图分类号:

张杰, 李昊, 程丝. 脑血管病的多组学研究[J]. 中国卒中杂志, 2025, 20(6): 657-662.

ZHANG Jie, LI Hao, CHENG Si. Multi-omics Research in Cerebrovascular Disease[J]. Chinese Journal of Stroke, 2025, 20(6): 657-662.

参考文献

[1] 中华人民共和国国家卫生健康委员会. 脑血管病防治指南（2024年版）[J]. 磁共振成像，2025，16（1）：1-8.
National Health Commission of the People’s Republic of China. Guideline for prevention and treatment of cerebrovascular disease（2024 edition）[J]. Chin J Magn Reson Imaging，2025，16（1）：1-8.
[2] BERGE E，WHITELEY W，AUDEBERT H，et al. European Stroke Organisation（ESO）guidelines on intravenous thrombolysis for acute ischaemic stroke[J]. Eur Stroke J，2021，6（1）：1-62.
[3] 熊云云，李光硕，马宇洁，等. 卒中：回眸2024[J]. 中国卒中杂志，2025，20（1）：1-19.
XIONG Y Y，LI G S，MA Y J，et al. Highlights in stroke in 2024[J]. Chin J Stroke，2025，20（1）：1-19.
[4] MENON B K，BUCK B H，SINGH N，et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada（AcT）：a pragmatic，multicentre，open-label，registry-linked，randomised，controlled，non-inferiority trial[J]. Lancet，2022，400（10347）：161-169.
[5] WANG Y J，LI S Y，PAN Y S，et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events（TRACE-2）：a phase 3，multicentre，open-label，randomised controlled，non-inferiority trial[J]. Lancet，2023，401（10377）：645-654.
[6] MENG X，LI S Y，DAI H G，et al. Tenecteplase vs. alteplase for patients with acute ischemic stroke：the ORIGINAL randomized clinical trial[J]. JAMA，2024，332（17）：1437-1445.
[7] ALBERS G W，JUMAA M，PURDON B，et al. Tenecteplase for stroke at 4.5 to 24 hours with perfusion-imaging selection[J]. N Engl J Med，2024，390（8）：701-711.
[8] XIONG Y Y，CAMPBELL B C V，SCHWAMM L H，et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy[J]. N Engl J Med，2024，391（3）：203-212.
[9] LI S Y，GU H Q，LI H，et al. Reteplase versus alteplase for acute ischemic stroke[J]. N Engl J Med，2024，390（24）：2264-2273.
[10] LI S Y，GU H Q，FENG B Y，et al. Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4.5 h after stroke onset（PROST-2）：a phase 3，open-label，non-inferiority，randomised controlled trial[J]. Lancet Neurol，2025，24（1）：33-41.
[11] MA L，HU X，SONG L L，et al. The third intensive care bundle with blood pressure reduction in acute cerebral haemorrhage trial（INTERACT3）：an international，stepped wedge cluster randomised controlled trial[J]. Lancet，2023，402（10395）：27-40.
[12] LI Q，YAKHKIND A，ALEXANDROV A W，et al. Code ICH：a call to action[J]. Stroke，2024，55（2）：494-505.
[13] ROTHWELL P M，GILES M F，CHANDRATHEVA A，et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke（EXPRESS study）：a prospective population-based sequential comparison[J]. Lancet，2007，370（9596）：1432-1442.
[14] WANG Y J，WANG Y L，ZHAO X Q，et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med，2013，369（1）：11-19.
[15] FISCHER U，KOGA M，STRBIAN D，et al. Early versus later anticoagulation for stroke with atrial fibrillation[J]. N Engl J Med，2023，388（26）：2411-2421.
[16] OLDGREN J，ÅSBERG S，HIJAZI Z，et al. Early versus delayed non-vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation（TIMING）：a registry-based randomized controlled noninferiority study[J]. Circulation，2022，146（14）：1056-1066.
[17] NGUYEN T N，ABDALKADER M，FISCHER U，et al. Endovascular management of acute stroke[J]. Lancet，2024，404（10459）：1265-1278.
[18] WANG Y J，MENG X，WANG A X，et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA[J]. N Engl J Med，2021，385（27）：2520-2530.
[19] MENG X，WANG A X，TIAN X，et al. One-year outcomes of early therapy with ticagrelor vs. clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA trial[J/OL]. Neurology，2024，102（3）：e207809[2025-05-28]. https://doi.org/10.1212/WNL.0000000000207809.
[20] 程丝，李昊. 卒中基因组学研究[J]. 中国卒中杂志，2023，18（2）：163-167.
CHENG S，LI H. Research in stroke genomics[J]. Chin J Stroke，2023，18（2）：163-167.
[21] YANG H，TING X，GENG Y H，et al. The risk variant rs11836367 contributes to breast cancer onset and metastasis by attenuating Wnt signaling via regulating NTN4 expression[J/OL]. Sci Adv，2022，8（23）：eabn3509[2025-05-28]. https://doi.org/10.1126/sciadv.abn3509.
[22] SANTOS R，URSU O，GAULTON A，et al. A comprehensive map of molecular drug targets[J]. Nat Rev Drug Discov，2017，16（1）：19-34.
[23] HALDIPUR P，ALDINGER K A，BERNARDO S，et al. Spatiotemporal expansion of primary progenitor zones in the developing human cerebellum[J]. Science，2019，366（6464）：454-460.
[24] SUN D X，GAO W，HU H X，et al. Why 90% of clinical drug development fails and how to improve it？[J]. Acta Pharm Sin B，2022，12（7）：3049-3062.
[25] 程丝，曾亚龙，李昊，等. 多组学研究助力卒中新药研发[J]. 中国卒中杂志，2022，17（3）：213-215.
CHENG S，ZENG Y L，LI H，et al. Multiomics studies facilitate stroke drug development[J]. Chin J Stroke，2022，17（3）：213-215.
[26] MONTANER J，RAMIRO L，SIMATS A，et al. Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke[J]. Nat Rev Neurol，2020，16（5）：247-264.
[27] MULLARD A. The UK biobank at 20[J]. Nat Rev Drug Discov，2022，21（9）：628-629.
[28] DEVINENI D，AKBARPOUR M，GONG Y F，et al. Inadequate use of newer treatments and glycemic control by cardiovascular risk and sociodemographic groups in US adults with diabetes in the NIH precision medicine initiative all of us research program[J]. Cardiovasc Drugs Ther，2024，38（2）：347-357.
[29] WANG B H，POZARICKIJ A，MAZIDI M，et al. Comparative studies of 2168 plasma proteins measured by two affinity-based platforms in 4000 Chinese adults[J/OL]. Nat Commun，2025，16（1）：1869[2025-05-28]. https://doi.org/10.1038/s41467-025-56935-2.
[30] WANG Y J，JING J，MENG X，et al. The third China national stroke registry（CNSR-Ⅲ）for patients with acute ischaemic stroke or transient ischaemic attack：design，rationale and baseline patient characteristics[J]. Stroke Vasc Neurol，2019，4（3）：158-164.
[31] CHENG S，XU Z，BIAN S Z，et al. The STROMICS genome study：deep whole-genome sequencing and analysis of 10 k Chinese patients with ischemic stroke reveal complex genetic and phenotypic interplay[J/OL]. Cell Discov，2023，9（1）：75[2025-05-28]. https://doi.org/10.1038/s41421-023-00582-8.
[32] 王秀杰，徐安定. 中国万人卒中多组学多模态数据库（STROMICS）：提升卒中精准诊疗的宝贵资源[J]. 中国卒中杂志，2024，19（12）：1369-1371.
WANG X J，XU A D. A comprehensive multi-omics and multimodal database of 10 k Chinese stroke patients（STROMICS）：a valuable resource for advancing precision medicine in stroke diagnosis and treatment[J]. Chin J Stroke，2024，19（12）：1369-1371.
[33] MISHRA A，MALIK R，HACHIYA T，et al. Stroke genetics informs drug discovery and risk prediction across ancestries[J]. Nature，2022，611（7934）：115-123.
[34] GARCÍA-BERROCOSO T，LLOBART V，COLÀS-CAMPÀSCOLAS-CAMPAS L，et al. Single cell immuno-laser microdissection coupled to label-free proteomics to reveal the proteotypes of human brain cells after ischemia[J]. Mol Cell Proteomics，2018，17（1）：175-189.
[35] DYKSTRA-AIELLO C，JICKLING G C，ANDER B P，et al. Altered expression of long noncoding RNAs in blood after ischemic stroke and proximity to putative stroke risk loci[J]. Stroke，2016，47（12）：2896-2903.
[36] SUN D K，TIEDT S，YU B，et al. A prospective study of serum metabolites and risk of ischemic stroke[J/OL]. Neurology，2019，92（16）：e1890-e1898[2025-05-28]. https://doi.org/10.1212/WNL.0000000000007279.
[37] GALLEGO-FABREGA C，CARRERA C，RENY J L，et al. PPM1A methylation is associated with vascular recurrence in aspirin-treated patients[J]. Stroke，2016，47（7）：1926-1929.
[38] HARPAZ D，ELTZOV E，SEET R C S，et al. Point-of-care-testing in acute stroke management：an unmet need ripe for technological harvest[J/OL]. Biosensors（Basel），2017，7（3）：30[2025-05-28]. https://doi.org/10.3390/bios7030030.
[39] MOORE D F，LI H，JEFFRIES N，et al. Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke：a pilot investigation[J]. Circulation，2005，111（2）：212-221.
[40] STAMOVA B，XU H C，JICKLING G，et al. Gene expression profiling of blood for the prediction of ischemic stroke[J]. Stroke，2010，41（10）：2171-2177.
[41] STAMOVA B，ANDER B P，JICKLING G，et al. The intracerebral hemorrhage blood transcriptome in humans differs from the ischemic stroke and vascular risk factor control blood transcriptomes[J]. J Cereb Blood Flow Metab，2019，39（9）：1818-1835.
[42] JIANG Y，CHENG S，SHI Y F，et al. Subtype-specific association of mitochondrial DNA copy number with poststroke/TIA outcomes in 10 241 patients in China[J]. Stroke，2024，55（5）：1261-1270.
[43] GOU L，LI H W，JIANG Y Y，et al. Non-O blood types are associated with a greater risk of large artery atherosclerosis stroke and dysregulation of cholesterol metabolism：an observational study[J/OL]. Lipids Health Dis，2024，23（1）：211[2025-05-28]. https://doi.org/10.1186/s12944-024-02199-6.
[44] SORIANO-TÁRRAGA C，MOLA-CAMINAL M，GIRALT-STEINHAUER E，et al. Biological age is better than chronological as predictor of 3-month outcome in ischemic stroke[J]. Neurology，2017，89（8）：830-836.
[45] CHEN L Y，PETERS J E，PRINS B，et al. Systematic Mendelian randomization using the human plasma proteome to discover potential therapeutic targets for stroke[J/OL]. Nat Commun，2022，13（1）：6143[2025-05-28]. https://doi.org/10.1038/s41467-022-33675-1.
[46] ZHANG C C，QIN F Q，LI X J，et al. Identification of novel proteins for lacunar stroke by integrating genome-wide association data and human brain proteomes[J/OL]. BMC Med，2022，20（1）：211[2025-05-28]. https://doi.org/10.1186/s12916-022-02408-y.
[47] OKADA Y，WU D，TRYNKA G，et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery[J]. Nature，2014，506（7488）：376-381.
[48] SAKAUE S，OKADA Y. GREP：genome for repositioning drugs[J]. Bioinformatics，2019，35（19）：3821-3823.